[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MY178894A - Therapeutic compositions containing macitentan - Google Patents

Therapeutic compositions containing macitentan

Info

Publication number
MY178894A
MY178894A MYPI2011000637A MYPI2011000637A MY178894A MY 178894 A MY178894 A MY 178894A MY PI2011000637 A MYPI2011000637 A MY PI2011000637A MY PI2011000637 A MYPI2011000637 A MY PI2011000637A MY 178894 A MY178894 A MY 178894A
Authority
MY
Malaysia
Prior art keywords
compositions containing
therapeutic compositions
compound
containing macitentan
macitentan
Prior art date
Application number
MYPI2011000637A
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY178894(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MY178894A publication Critical patent/MY178894A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.
MYPI2011000637A 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan MY178894A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13

Publications (1)

Publication Number Publication Date
MY178894A true MY178894A (en) 2020-10-21

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011000637A MY178894A (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Country Status (29)

Country Link
US (3) US8809334B2 (en)
EP (2) EP3300729B1 (en)
JP (3) JP5764061B2 (en)
KR (1) KR101678699B1 (en)
CN (1) CN102099026B (en)
AR (1) AR073031A1 (en)
AU (1) AU2009280843B2 (en)
BR (1) BRPI0917661B8 (en)
CA (1) CA2731370C (en)
CY (2) CY1119826T1 (en)
DK (2) DK2315587T3 (en)
ES (2) ES2652590T3 (en)
HK (1) HK1253355B (en)
HR (2) HRP20171917T1 (en)
HU (2) HUE036071T2 (en)
IL (1) IL211143A0 (en)
LT (2) LT2315587T (en)
MA (1) MA32614B1 (en)
MX (1) MX350011B (en)
MY (1) MY178894A (en)
NO (1) NO2315587T3 (en)
NZ (1) NZ591601A (en)
PL (2) PL2315587T3 (en)
PT (2) PT2315587T (en)
RU (1) RU2519161C2 (en)
SI (2) SI3300729T1 (en)
TW (1) TWI446911B (en)
WO (1) WO2010018549A2 (en)
ZA (1) ZA201101900B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621273C (en) 2005-09-12 2014-07-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (en) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Iron with actively cooled soleplate and method for cooling the soleplate.
BRPI0908491A2 (en) 2008-02-28 2015-08-11 Nippon Shinyaku Co Ltd Fibrosis inhibitor
DK2315587T3 (en) 2008-08-13 2018-01-02 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (en) 2013-01-11 2022-11-11 Corsair Pharma Inc Treprostinil Prodrugs
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
BR112019012251A2 (en) 2016-12-14 2019-11-05 Respira Therapeutics Inc methods and compositions for treating pulmonary hypertension and other pulmonary disorders
MX2021001820A (en) * 2018-09-14 2021-04-28 Pharmosa Biopharm Inc Pharmaceutical composition for controlled release of weak acid drugs and uses thereof.
SI3897646T1 (en) 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Macitentan for the treatment of pulmonary arterial hypertension
TW202042818A (en) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition for the treatment of chronic thromboembolic pulmonary hypertension
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1097239A (en) 1976-05-11 1981-03-10 Salvador Moncada Enzymatic preparation of prostacyclin and its salts
DE2845770A1 (en) 1978-10-19 1980-04-30 Schering Ag NEW PROSTACYCLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
JPS58124778A (en) 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
CA2431077A1 (en) * 2000-12-19 2002-06-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
DE10100426B4 (en) 2001-01-08 2006-04-06 Steag Hamatech Ag Method and device for joining substrates
TWI316055B (en) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
JP4769460B2 (en) 2002-12-02 2011-09-07 アクテリオン ファーマシューティカルズ リミテッド New sulfamides
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
CA2621273C (en) 2005-09-12 2014-07-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (en) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS
CA2714608A1 (en) 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer
DK2315587T3 (en) 2008-08-13 2018-01-02 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN

Also Published As

Publication number Publication date
EP3300729B1 (en) 2019-10-09
SI3300729T1 (en) 2020-02-28
TW201010985A (en) 2010-03-16
BRPI0917661B1 (en) 2019-12-17
MX350011B (en) 2017-08-22
PL2315587T3 (en) 2018-03-30
JP2011530581A (en) 2011-12-22
JP2015180683A (en) 2015-10-15
PT3300729T (en) 2020-01-20
RU2011109084A (en) 2012-09-20
JP5956025B2 (en) 2016-07-20
US20140329824A1 (en) 2014-11-06
ZA201101900B (en) 2012-08-29
HK1253355A1 (en) 2019-06-14
US20110136818A1 (en) 2011-06-09
RU2519161C2 (en) 2014-06-10
HUE047767T2 (en) 2020-05-28
DK3300729T3 (en) 2020-01-20
JP2015187148A (en) 2015-10-29
SI2315587T1 (en) 2018-04-30
BRPI0917661A2 (en) 2015-12-01
WO2010018549A3 (en) 2010-07-29
US9173881B2 (en) 2015-11-03
IL211143A0 (en) 2011-04-28
CY1122641T1 (en) 2021-03-12
CN102099026B (en) 2012-08-29
US8809334B2 (en) 2014-08-19
CA2731370A1 (en) 2010-02-18
MA32614B1 (en) 2011-09-01
WO2010018549A2 (en) 2010-02-18
AR073031A1 (en) 2010-10-06
ES2652590T3 (en) 2018-02-05
EP2315587B1 (en) 2017-10-25
HRP20171917T1 (en) 2018-02-09
AU2009280843B2 (en) 2015-03-05
TWI446911B (en) 2014-08-01
BRPI0917661B8 (en) 2021-05-25
JP5764061B2 (en) 2015-08-12
NO2315587T3 (en) 2018-03-24
MX2011001625A (en) 2011-03-29
HRP20192204T1 (en) 2020-03-06
CA2731370C (en) 2017-03-14
LT2315587T (en) 2018-01-10
AU2009280843A1 (en) 2010-02-18
PT2315587T (en) 2018-01-31
CY1119826T1 (en) 2018-06-27
KR20110045006A (en) 2011-05-03
NZ591601A (en) 2012-12-21
LT3300729T (en) 2020-01-10
JP5956026B2 (en) 2016-07-20
HK1253355B (en) 2020-06-19
DK2315587T3 (en) 2018-01-02
US20160022678A1 (en) 2016-01-28
PL3300729T3 (en) 2020-04-30
EP2315587A2 (en) 2011-05-04
ES2763176T3 (en) 2020-05-27
EP3300729A1 (en) 2018-04-04
KR101678699B1 (en) 2016-11-23
CN102099026A (en) 2011-06-15
HUE036071T2 (en) 2018-06-28
US9597331B2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
MY178894A (en) Therapeutic compositions containing macitentan
UA94833C2 (en) Substituted bicyclolactams
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
MY146924A (en) Substituted imidazoheterocycles
MX2012003389A (en) Pyrrolidine gpr40 modulators.
TN2011000222A1 (en) Melanocortin receptor agonists
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
UA92670C2 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon
MX2010008993A (en) 2-aza-bicyclo[2.2.1]heptane derivatives.
TW200833328A (en) 2-aza-bicyclo[3.1.0]hexane derivatives
PT2421879E (en) Novel 7-deazapurine nucleosides for therapeutic uses
HK1158192A1 (en) Piperidine gpcr agonists
MX2008013196A (en) 5-amido-2-carboxamide indoles.
TW200612958A (en) Substituted imidazole derivatives
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
PT2310356E (en) Adamantyl diamide derivatives and uses of same
HK1157329A1 (en) Piperidinyl gpcr agonists
MX353209B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE.
MX2009010552A (en) Peripheral opioid receptor antagonists and uses thereof.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2009008028A (en) Benzofuran antiparasitic agents.
EP2238105A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MA32834B1 (en) Aminocyclopentaneicarboxamide 3 acts as a shimokin receptor modulator